Lexicon Pharmaceuticals (NASDAQ: LXRX) net income
Lexicon Pharmaceuticals reported a net loss of $50.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $200.4m. Earnings per share were −$0.14.
Lexicon Pharmaceuticals's best year of the last 10 was fiscal 2019. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$50.3m | — | −101.1% | −$0.14 |
| 2024 | −$200.4m | — | −644.8% | −$0.63 |
| 2023 | −$177.1m | — | −14,710.9% | −$0.80 |
| 2022 | −$101.9m | — | −73,341.0% | −$0.62 |
| 2021 | −$87.8m | — | −29,449.0% | −$0.60 |
| 2020 | −$58.6m | −145.0% | −244.1% | −$0.53 |
| 2019 | $130.1m | — | 40.4% | $1.23 |
| 2018 | −$120.5m | — | −190.7% | −$1.14 |
| 2017 | −$123.0m | — | −134.1% | −$1.17 |
| 2016 | −$131.4m | — | −165.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lexicon Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Lexicon Pharmaceuticals ranks 256th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Lexicon Pharmaceuticals, −101.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 254th | Septerna | −$48.9m | −106.4% |
| 255th | Opus Genetics | −$49.6m | −349.3% |
| 256th | Lexicon Pharmaceuticals | −$50.3m | −101.1% |
| 257th | Sagimet Biosciences | −$51.0m | — |
| 258th | Establishment Labs | −$51.1m | −24.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Lexicon Pharmaceuticals
- How much did Lexicon Pharmaceuticals earn in fiscal 2025?
- Lexicon Pharmaceuticals reported a net loss of $50.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $200.4m.
- What are the earnings per share of Lexicon Pharmaceuticals?
- They were −$0.14 in fiscal 2025, compared with −$0.63 in fiscal 2024.
- What was the most profitable year for Lexicon Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2019, with $130.1m.
- Where does Lexicon Pharmaceuticals rank in its sector by net income?
- It ranks 256th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Lexicon Pharmaceuticals come from?
- From the annual report (Form 10-K) that Lexicon Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lexicon Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Lexicon Pharmaceuticals: the Lexicon Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.